Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth

Exclusion Criteria

• •Damaged skin in or around test sites
• •History of any acute (e.g. acute infections) or chronic illness or known skin cancer that might confound the results of the trial
• •History or clinical signs of keloids or hypertrophic scars
• •Immunological disorders such as alopecia areata, and systemic lupus erythematosus
• •Current or within 2 weeks prior to first dosing use of vasodilating drugs (e.g. Pentoxifyllin, nitroglycerine) or anticoagulating drugs (e.g. heparine, cumarines, new oral anticoagulants)
• •Current or within 3 months prior to first dosing use of anti-inflammatory medication, corticosteroids or immunosuppressive drugs taken for more than 2 consecutive weeks
• •Current or within 3 months prior to first dosing use of medication with hair growth modifying properties like minoxidil, diazoxid, cyclosporine, antiandrogens
• •Current or within 12 months prior to first dosing intake of anabolics or 5-alpha reductase inhibitors
• •Current or within one week prior to first dosing use of any topical drugs on the legs